首页> 外文期刊>Assay and drug development technologies >Systematically Prioritizing Candidates in Genome-Based Drug Repurposing
【24h】

Systematically Prioritizing Candidates in Genome-Based Drug Repurposing

机译:在基于基因组的药物再利用中系统地优先考虑候选药物

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Drug repurposing is the application of approved drugs to treat diseases separate and distinct from their original indications. Herein, we define the scope of all practical precision drug repurposing using DrugBank, a publicly available database of pharmacological agents, and BioVU, a large, de-identified DNA repository linked to longitudinal electronic health records at Vanderbilt University Medical Center. We present a method of repurposing candidate prioritization through integration of pharmacodynamic and marketing variables from DrugBank with quality control thresholds for genomic data derived from the DNA samples within BioVU. Through the synergy of delineated “target-action pairs,” along with target genomics, we identify ~230 “pairs” that represent all practical opportunities for genomic drug repurposing. From this analysis, we present a pipeline of 14 repurposing candidates across 7 disease areas that link to our repurposability platform and present high potential for randomized controlled trial startup in upcoming months.
机译:药物再利用是应用已批准的药物来治疗与其原始适应症分开和不同的疾病。在此,我们使用 DrugBank(一个公开可用的药理学药物数据库)和 BioVU(一个与范德比尔特大学医学中心纵向电子健康记录相关的大型去识别化 DNA 存储库)定义了所有实用的精准药物再利用的范围。我们提出了一种通过整合来自DrugBank的药效学和营销变量以及来自BioVU中DNA样本的基因组数据的质量控制阈值来重新利用候选药物优先级的方法。通过描述的“靶向-作用对”以及靶标基因组学的协同作用,我们确定了~230个“对”,它们代表了基因组药物再利用的所有实际机会。通过这一分析,我们展示了一个由7个疾病领域的14个再利用候选药物组成的管线,这些候选药物与我们的再利用性平台相关联,并在未来几个月内为随机对照试验的启动提供了巨大的潜力。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号